Kallikrein and Male Subfertility. Usefulness of High-Unit Kallikrein Tablets

Publisher Website
Google Scholar
Abstract
The therapeutic effect of long-term oral administration of Kallikrein tablets was studied on male subfertility. Subjects were 26 patients with poor sperm motility and divided into 2 groups according to the rate of motile spermatozoa: < 40% (group A:9 cases) and .gtoreq. 40% (group B: 17 cases). Patients in group A were administered 600 K.U. [Kallikrein unit]/day orally for 6 mo. and those of group B received 300 K.U./day for 3 mo. and 600 K.U./day for the ensuing 3 mo. The changes of semen parameters during the treatment were as follows: no increase in sperm count; significant improvement of quantitative and qualitative sperm motility; improvement of sperm morphology; significant increase in total number of motile spermatozoa; volume of semen was increased without statistical significance. Testosterone, follicle stimulating hormone and luteinizing hormone levels in blood plasma did not change significantly. The constituents of seminal plasma (fructose, cholesterol, alkaline phosphatase, ACP [acid phosphatase], GOT [glutamic oxalacetic transaminase] and LDH [lactate dehydrogenase]) were determined. Although ACP and GOT showed an increasing tendency and ALP tended to decrease during treatment, no biochemical parameter changing parallel with therapeutic results was found. Eight of the 26 subjects successfully impregnated their wives (conception rate: 30.8%). No remarkable side effect was detected.